vs
Side-by-side financial comparison of BRUNSWICK CORP (BC) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.
BRUNSWICK CORP is the larger business by last-quarter revenue ($1.4B vs $878.4M, roughly 1.6× EXACT SCIENCES CORP). BRUNSWICK CORP runs the higher net margin — 1.5% vs -9.8%, a 11.3% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 17.3%). EXACT SCIENCES CORP produced more free cash flow last quarter ($120.4M vs $-116.8M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs -2.3%).
Brunswick Corporation, formerly known as the Brunswick-Balke-Collender Company, is an American corporation that has been developing, manufacturing and marketing a wide variety of products since 1845. Brunswick has more than 13,000 employees in 24 countries. Brunswick owns a number of brands, including Mercury Marine. In 2024, Brunswick reported sales of US$5.2 billion. Brunswick's global headquarters is in the northern Chicago suburb of Mettawa, Illinois.
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
BC vs EXAS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $878.4M |
| Net Profit | $21.0M | $-86.0M |
| Gross Margin | 24.9% | 70.1% |
| Operating Margin | 3.6% | -9.4% |
| Net Margin | 1.5% | -9.8% |
| Revenue YoY | 17.3% | 23.1% |
| Net Profit YoY | — | 90.1% |
| EPS (diluted) | $0.32 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $878.4M | ||
| Q3 25 | $1.4B | $850.7M | ||
| Q2 25 | $1.4B | $811.1M | ||
| Q1 25 | $1.2B | $706.8M | ||
| Q4 24 | $1.2B | $713.4M | ||
| Q3 24 | $1.3B | $708.7M | ||
| Q2 24 | $1.4B | $699.3M |
| Q1 26 | $21.0M | — | ||
| Q4 25 | $18.7M | $-86.0M | ||
| Q3 25 | $-235.5M | $-19.6M | ||
| Q2 25 | $59.3M | $-1.2M | ||
| Q1 25 | $20.2M | $-101.2M | ||
| Q4 24 | $-82.5M | $-864.6M | ||
| Q3 24 | $44.6M | $-38.2M | ||
| Q2 24 | $100.0M | $-15.8M |
| Q1 26 | 24.9% | — | ||
| Q4 25 | 23.1% | 70.1% | ||
| Q3 25 | 25.8% | 68.6% | ||
| Q2 25 | 25.5% | 69.3% | ||
| Q1 25 | 24.9% | 70.8% | ||
| Q4 24 | 21.9% | 69.0% | ||
| Q3 24 | 26.2% | 69.4% | ||
| Q2 24 | 27.1% | 69.8% |
| Q1 26 | 3.6% | — | ||
| Q4 25 | 3.1% | -9.4% | ||
| Q3 25 | -17.8% | -3.0% | ||
| Q2 25 | 7.1% | -0.3% | ||
| Q1 25 | 4.6% | -13.6% | ||
| Q4 24 | -4.8% | -122.8% | ||
| Q3 24 | 7.7% | -5.6% | ||
| Q2 24 | 11.0% | -3.8% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 1.4% | -9.8% | ||
| Q3 25 | -17.3% | -2.3% | ||
| Q2 25 | 4.1% | -0.1% | ||
| Q1 25 | 1.7% | -14.3% | ||
| Q4 24 | -7.1% | -121.2% | ||
| Q3 24 | 3.5% | -5.4% | ||
| Q2 24 | 6.9% | -2.3% |
| Q1 26 | $0.32 | — | ||
| Q4 25 | $0.32 | $-0.45 | ||
| Q3 25 | $-3.59 | $-0.10 | ||
| Q2 25 | $0.89 | $-0.01 | ||
| Q1 25 | $0.30 | $-0.54 | ||
| Q4 24 | $-1.21 | $-4.69 | ||
| Q3 24 | $0.67 | $-0.21 | ||
| Q2 24 | $1.48 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $277.8M | $964.7M |
| Total DebtLower is stronger | $490.2M | — |
| Stockholders' EquityBook value | $1.6B | $2.4B |
| Total Assets | $5.5B | $5.9B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $277.8M | — | ||
| Q4 25 | $256.8M | $964.7M | ||
| Q3 25 | $297.7M | $1.0B | ||
| Q2 25 | $315.7M | $858.4M | ||
| Q1 25 | $286.7M | $786.2M | ||
| Q4 24 | $269.0M | $1.0B | ||
| Q3 24 | $284.1M | $1.0B | ||
| Q2 24 | $494.5M | $946.8M |
| Q1 26 | $490.2M | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.6B | $2.5B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | $1.9B | $2.4B | ||
| Q4 24 | $1.9B | $2.4B | ||
| Q3 24 | $2.0B | $3.2B | ||
| Q2 24 | $2.0B | $3.2B |
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.3B | $5.9B | ||
| Q3 25 | $5.4B | $5.9B | ||
| Q2 25 | $5.8B | $5.8B | ||
| Q1 25 | $5.9B | $5.7B | ||
| Q4 24 | $5.7B | $5.9B | ||
| Q3 24 | $6.0B | $6.7B | ||
| Q2 24 | $6.4B | $6.7B |
| Q1 26 | 0.31× | — | ||
| Q4 25 | 1.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $151.7M |
| Free Cash FlowOCF − Capex | $-116.8M | $120.4M |
| FCF MarginFCF / Revenue | -8.5% | 13.7% |
| Capex IntensityCapex / Revenue | 4.2% | 3.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $344.6M | $356.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $132.9M | $151.7M | ||
| Q3 25 | $140.4M | $219.9M | ||
| Q2 25 | $316.2M | $89.0M | ||
| Q1 25 | $-27.4M | $30.8M | ||
| Q4 24 | $306.4M | $47.1M | ||
| Q3 24 | $67.4M | $138.7M | ||
| Q2 24 | $211.0M | $107.1M |
| Q1 26 | $-116.8M | — | ||
| Q4 25 | $83.6M | $120.4M | ||
| Q3 25 | $106.5M | $190.0M | ||
| Q2 25 | $271.3M | $46.7M | ||
| Q1 25 | $-65.1M | $-365.0K | ||
| Q4 24 | $276.1M | $10.7M | ||
| Q3 24 | $31.4M | $112.6M | ||
| Q2 24 | $163.9M | $71.2M |
| Q1 26 | -8.5% | — | ||
| Q4 25 | 6.3% | 13.7% | ||
| Q3 25 | 7.8% | 22.3% | ||
| Q2 25 | 18.7% | 5.8% | ||
| Q1 25 | -5.3% | -0.1% | ||
| Q4 24 | 23.9% | 1.5% | ||
| Q3 24 | 2.5% | 15.9% | ||
| Q2 24 | 11.4% | 10.2% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.7% | 3.6% | ||
| Q3 25 | 2.5% | 3.5% | ||
| Q2 25 | 3.1% | 5.2% | ||
| Q1 25 | 3.1% | 4.4% | ||
| Q4 24 | 2.6% | 5.1% | ||
| Q3 24 | 2.8% | 3.7% | ||
| Q2 24 | 3.3% | 5.1% |
| Q1 26 | — | — | ||
| Q4 25 | 7.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.33× | — | ||
| Q1 25 | -1.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.51× | — | ||
| Q2 24 | 2.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BC
Segment breakdown not available.
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
